ArticleCell death and differentiation2026
Disruption of cellular iron homeostasis by SRPX2-IRP1 interaction aggravates renal fibrosis in chronic kidney disease.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Disrupted iron homeostasis is a critical pathological feature of chronic kidney disease (CKD) and drives renal fibrosis and disease progression, but the underlying regulatory mechanisms linking iron dysregulation to renal fibrosis remain poorly defined. Here, we identify sushi repeat-containing protein X-linked 2 (SRPX2) as a novel pathogenic regulator of renal fibrosis that dysregulates tubular cellular iron metabolism. Clinical validation revealed that SRPX2 expression was significantly elevated in kidney biopsy tissues and serum samples of CKD patients with various renal pathological types, serving as a potential biomarker for CKD progression. In two classic mouse renal fibrosis models of unilateral ureteral obstruction (UUO) and folic acid (FA)-induced nephropathy, as well as in TGF-β1-stimulated human renal tubular epithelial HK-2 cells, SRPX2 was significantly upregulated in a time- and dose-dependent manner through the TGFβR1/SMAD2/3 signaling pathway. Global and TEC-specific ablation of Srpx2 was sufficient to attenuate kidney injury and fibrosis. Mechanistically, SRPX2 physically interacted with iron regulatory protein 1 (IRP1), a central coordinator of cellular iron homeostasis. This interaction disrupted the IRP1/iron-responsive element regulatory system, leading to decreased expression of iron import protein (TFR1) and increased expression of iron storage (FTH1) and export (FPN) proteins, ultimately triggering intracellular iron dyshomeostasis. Moreover, proteomic and transcriptional profiling of clinical CKD samples and UUO mouse kidneys further confirmed the significant dysregulation of iron ion metabolism during renal fibrosis progression. Notably, therapeutic iron dextran supplementation alleviated UUO-induced renal fibrosis. Collectively, our findings reveal SRPX2 as a key pathogenic factor driving renal fibrosis by disrupting tubular iron homeostasis. Targeting the SRPX2-IRP1 regulatory axis presents a promising therapeutic strategy for slowing CKD progression.
Identifiers
42733101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.